CERTERA's objective is to create a coordinated research and innovation structure to accelerate the preclinical and early stage clinical development of these types of therapies.
The Spanish Agency for Medicines and Health Products (AEMPS) defines them advanced therapies as medicines for human use that may be based on genes (gene therapy), cells (cellular therapy) or fabrics (...
Spain is positioned as a leader and benchmark country in advanced therapies, the cornerstone for the treatment of diseases such as cancer, where 62% of clinical trials are conducted.
The initiatives are part of the RIS3CAT Community accredited by the Government of Catalonia and coordinated by Biocat to improve the Catalan healthcare system and tackle health-related challenges